© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
A panel of experts reflect on how to treat patients with advanced renal cell carcinoma by reviewing clinical trial data and discussing patient cases.
November 19th 2021
Tian Zhang, MD, MHS, and Moshe Orenstein, MD, MA, recall data from two clinical trials for first-line treatment of advanced renal cell carcinoma: CheckMate-9ER and CheckMate-214.
David A. Braun, MD, PhD continues the first-line clinical trial discussion with the addition of KEYNOTE-426 and CLEAR trial data.
December 3rd 2021
Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.
The panel continues their conversation about the first patient case.
December 13th 2021
Dr Orenstein details how he manages quality of life for patients with advanced renal cell carcinoma.
Dr Choueiri presents the second patient case to the panel: a 53-year-old woman with renal cell carcinoma that underwent a nephrectomy.
December 17th 2021
Patient Case 2 continues, and Drs Zhang and Orenstein discuss second-line trials for advanced renal cell carcinoma.
Dr Braun closes out the clinical trial dialogue by discussing the CONTACT-03 and Tivo-3 trials.
December 23rd 2021
A panel of experts explain what they do within their clinical practices to select second- or later-line therapies for patients with advanced renal cell carcinoma.
Drs Orenstein and Braun close out the program by examining unmet needs in the advanced renal cell carcinoma treatment space, as well as emerging options.